| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | -7711.98% | -14686.17% | -476.23% | -403.52% |
| EBITDA Margin | — | — | -7643.88% | -14680.72% | -476.23% | — |
| Net Margin | — | — | -7304.73% | -14625.85% | -476.88% | -407.73% |
| Current Ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | — |
| Quick Ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | — |
| Debt / Equity | — | — | 0.03 | — | 0.01 | — |
| ROE | -27.91% | -29.01% | -173.34% | -85.83% | -38.49% | -29.11% |
| ROA | -26.63% | -27.91% | -131.17% | -72.40% | -34.82% | -19.27% |
| Asset Turnover | — | 0.00 | 0.02 | 0.00 | 0.07 | 0.05 |
| Book Value / Share | 1.76 | 4.00 | 2.06 | 0.83 | 2.11 | 1.19 |
Inhibikase Therapeutics Inc. is a biotechnology company dedicated to the development and commercialization of therapeutics for neurodegenerative diseases and infectious diseases that impact the nervous system. The company focuses on creating innovative drugs aimed at interrupting biological pathways contributing to these diseases. Its leading programs target conditions such as Parkinson’s disease and related disorders, offering potential new treatment options for these debilitating conditions. Inhibikase Therapeutics employs a proprietary platform for drug development, emphasizing the need for precise and effective treatments. The company holds a significant position in the biopharmaceutical sector as it works towards improving healthcare options for neurological conditions. With its ongoing research and development efforts, Inhibikase Therapeutics plays a crucial role in addressing unmet medical needs, contributing to advancements in biotech and medical science.